Best of Oncology Podcast Series

263 Episodes

1. SABCS HIGHLIGHTS 2023 ROUNDTABLE DISCUSSION: MonarchE Trial

   Published: 21/12/2023
2. SABCS HIGHLIGHTS 2023 ROUNDTABLE DISCUSSION: NATALEE Trial – Final Results

   Published: 21/12/2023
3. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Results from the Phase 1b MonumenTAL-2 Study

   Published: 18/12/2023
4. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Prophylactic Tocilizumab to Prevent CRS with Teclistamab Administration

   Published: 18/12/2023
5. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: RRMM Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

   Published: 18/12/2023
6. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: The Phase 2 CARTITUDE-2 Trial

   Published: 18/12/2023
7. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: CC-95266, a GPRC5D-Targeted CAR T-Cell Therapy for RRMM

   Published: 18/12/2023
8. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Multiple Myeloma

   Published: 18/12/2023
9. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Optimum / Muknine Trial

   Published: 18/12/2023
10. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Iskia Trial

    Published: 18/12/2023
11. ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: PERSEUS Trial

    Published: 18/12/2023
12. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Nivolumab-AVD vs Bv-AVD in Older Patients with Advanced Stage Hodgkin Lymphoma: SWOG S1826

    Published: 18/12/2023
13. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Early-Stage and Advanced Classical Hodgkin Lymphoma

    Published: 18/12/2023
14. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Primary Results of the Phase 1 & Phase 2 VALENTINE-PTCL01 Study

    Published: 18/12/2023
15. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Report of the Phase III UK NCRI FLAIR Study

    Published: 18/12/2023
16. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

    Published: 18/12/2023
17. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients

    Published: 18/12/2023
18. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: CARs T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma

    Published: 18/12/2023
19. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Glofitamab (Glofit) Plus R-CHOP: Preliminary Safety And Efficacy Results

    Published: 18/12/2023
20. ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

    Published: 18/12/2023